|
|
|
14 August 2020
Timothy Lee, Senior Vice President of Legal and Public Affairs at the Center for Individual Freedom, discusses President Trump's executive orders on drug pricing and the negative consequences of government price controls on innovation and to consumers.
0:00
0:00
Related Podcasts
04 December 2025
Phil Kerpen, President and Founder of American Commitment, discusses the recent drug-pricing deal negotiated by the Trump administration with the United Kingdom, the multiple benefits the agreement will have for Americans and drug innovation, why taxpayer subsidies to health insurers will not lower healthcare costs, and why price controls for credit card transactions are a bad idea.
02 September 2024
Sally Pipes, Founder and President of Pacific Research Institute, discusses the impact of drug price controls under the Inflation Reduction Act (IRA), what it means for research and development of life-saving medicines, and how the IRA's drug pricing provisions will reduce access to new cures and treatments and result in longer wait times for existing medicines.
03 December 2021
Phil Kerpen, Founder and President of American Commitment, discusses how drug price controls would hurt seniors as they would reduce access to and undermine research and development in life-saving biopharmaceuticals, and why the Build Back Better Act under consideration in Congress is riddled with other disastrous provisions.
17 September 2020
Sally Pipes, President, CEO and Thomas W. Smith Fellow in Health Care Policy at the Pacific Research Institute, discusses President Trump’s recent executive order regarding drug pricing, how importing foreign drug price controls could curtail innovation and limit access to the newest drugs, and why the timing of such a policy is wrong amid the ongoing COVID-19 pandemic.
14 February 2020
Timothy Lee, Senior Vice President of Legal and Public Affairs at CFIF, discusses the DOJ's civil antitrust lawsuit seeking to block Sabre Corporation's acquisition of Farelogix, Inc., and why imported price controls for drugs is a prescription for failure.
03 May 2019
Phil Kerpen, President of American Commitment, discusses prescription drug prices, the fundamental problems with importing foreign price controls, and the steps Congress can take to improve the system.
